Health, pharma, science writer for Reuters. Any opinions are mine.

GSK chairman rules out near-term break-up of drugmaker

uk.reuters.com — LONDON A break-up of GlaxoSmithKline (GSK.L) is not something that is being considered "at all" at present, the chairman of Britain's biggest drugmaker said on Thursday. Philip Hampton, who became chairman a year ago, told GSK's annual meeting that the focus was on boosting the performance of the group's consumer division, which sells products ranging from headache pills to toothpaste.

GlaxoSmithKline chairman rules out break-up in near term

GlaxoSmithKline chairman rules out break-up in near term
dailymail.co.uk — LONDON, May 5 (Reuters) - GlaxoSmithKline's chairman said on Thursday that a break-up of the pharmaceuticals group is not something that is being considered at all at present. Philip Hampton, who became chairman a year ago, said at GSK's annual meeting that the focus was on boosting the performance of the group's consumer division, which sells products ranging from headache pills to toothpaste.

UPDATE 1-China weighs on Smith & Nephew's first-quarter revenue

UPDATE 1-China weighs on Smith & Nephew's first-quarter revenue
reuters.com — First-quarter revenue $1.14 billion vs consensus $1.16 bln * Company sees improvement in China in second half (Adds CFO comments, shares, background) By Ben Hirschler LONDON, May 5 Smith & Nephew, Europe's biggest maker of artificial knees and hips, reported a smaller than expected 3 percent rise in first-quarter revenue on Thursday after weakness in China and the oil-rich Gulf states offset good U.S.

Europe could recommend second biosimilar arthritis drug this week

Europe could recommend second biosimilar arthritis drug this week
reuters.com — LONDON Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel.

Shire jumps as Vyvanse drug helps it to beat earnings forecast

Shire jumps as Vyvanse drug helps it to beat earnings forecast
dailymail.co.uk — LONDON, April 29 (Reuters) - Strong demand for Shire's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12 percent, boosting the London-listed group's shares ahead of its $32 billion acquisition of U.S. rare diseases specialist Baxalta.

AstraZeneca broadens focus on cancer treatments

AstraZeneca broadens focus on cancer treatments
bdlive.co.za — LONDON - AstraZeneca is increasing its focus on cancer treatments in a drive to streamline operations after underlying earnings, hit by drug patent expiries, fell 12% in the first quarter, broadly in line with analyst expectations. CEO Pascal Soriot said on Friday that he would sharpen the prioritisation of investments and increase spending in oncology while cutting commercial and manufacturing operations.

Reformulated GSK mouthwash endorsed as umbilical cord antiseptic

Reformulated GSK mouthwash endorsed as umbilical cord antiseptic
businessinsider.com — By Ben Hirschler LONDON (Reuters) - An antiseptic gel to stop umbilical cord infections in newborn babies was recommended as safe and effective by European regulators on Friday in a boost for GlaxoSmithKline scientists who developed it from a mouthwash.

AstraZeneca, in earnings trough, doubles down on cancer drugs

AstraZeneca, in earnings trough, doubles down on cancer drugs
uk.reuters.com — LONDON AstraZeneca (AZN.L) is increasing its focus on cancer treatments in a drive to streamline operations after underlying earnings, hit by drug patent expiries, fell 12 percent in the first quarter, broadly in line with analyst expectations. Chief Executive Pascal Soriot said on Friday that he would sharpen the prioritisation of investments and increase spending in oncology while cutting commercial and manufacturing operations.

Reformulated GSK mouthwash endorsed as umbilical cord antiseptic

Reformulated GSK mouthwash endorsed as umbilical cord antiseptic
reuters.com — LONDON An antiseptic gel to stop umbilical cord infections in newborn babies was recommended as safe and effective by European regulators on Friday in a boost for GlaxoSmithKline scientists who developed it from a mouthwash.

Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation

Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
ca.finance.yahoo.com — By Ben Hirschler and Leigh Thomas LONDON/PARIS (Reuters) - French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover battle after the U.S. cancer firm rebuffed its approaches.
More Articles →
May 04, 2016

Exclusive: #Pfizer approaches #Medivation about potential takeover - sources reut.rs/1X7hBEc $MDVN $PFE $SASY


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.